Cargando…

The prognosis value of EphA3 and the androgen receptor in prostate cancer treated with radical prostatectomy

BACKGROUND: This study aimed to preliminarily assess the relationship between erythropoietin‐producing hepatocellular carcinoma receptor A3 (EphA3) and androgen receptor (AR) protein expression levels and prognosis in prostate cancer (PCa) to better understand the role of EphA3 in the prognosis and...

Descripción completa

Detalles Bibliográficos
Autores principales: Duan, Xiuzhi, Xu, Xiaoming, Yin, Binbin, Hong, Bong, Liu, Weiwei, Liu, Qian, Tao, Zhihua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6595293/
https://www.ncbi.nlm.nih.gov/pubmed/30958616
http://dx.doi.org/10.1002/jcla.22871
_version_ 1783430375824949248
author Duan, Xiuzhi
Xu, Xiaoming
Yin, Binbin
Hong, Bong
Liu, Weiwei
Liu, Qian
Tao, Zhihua
author_facet Duan, Xiuzhi
Xu, Xiaoming
Yin, Binbin
Hong, Bong
Liu, Weiwei
Liu, Qian
Tao, Zhihua
author_sort Duan, Xiuzhi
collection PubMed
description BACKGROUND: This study aimed to preliminarily assess the relationship between erythropoietin‐producing hepatocellular carcinoma receptor A3 (EphA3) and androgen receptor (AR) protein expression levels and prognosis in prostate cancer (PCa) to better understand the role of EphA3 in the prognosis and progression of PCa. MATERIALS: We investigated the expression of EphA3 and AR in human PCa by immunohistochemistry. RESULTS: EphA3 and AR were both significantly upregulated in PCa, with expression mainly localized to the nucleus. A high level of AR expression was found in 48.4% of 64 tumor samples, which was significantly more than in the adjacent tissue samples (15.6%) (P < 0.01). The percentage of samples expressing a high level of EphA3 was significantly greater in the PCa samples (54.7%) than in the adjacent tissue samples (20.3%) for the 64 tumors (P < 0.01). The high levels of EphA3 and AR expression in the PCa tissue samples were both correlated with the pathological stage, bladder and rectal invasion, distant metastasis, and preoperative PSA level (both P < 0.05). The survival time was significantly shorter in high levels of AR expression of patients. (P < 0.01). A high level of EphA3 in PCa patients suggests a poor prognosis (P < 0.05). Biochemical recurrence, distant metastasis, and the final scores of EphA3 and AR expression were significantly correlated with the prognosis of PCa (P < 0.05). CONCLUSIONS: Increased EphA3 expression is an independent prognostic factor for a poor outcome and decreased survival in PCa.
format Online
Article
Text
id pubmed-6595293
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-65952932019-11-12 The prognosis value of EphA3 and the androgen receptor in prostate cancer treated with radical prostatectomy Duan, Xiuzhi Xu, Xiaoming Yin, Binbin Hong, Bong Liu, Weiwei Liu, Qian Tao, Zhihua J Clin Lab Anal Research Articles BACKGROUND: This study aimed to preliminarily assess the relationship between erythropoietin‐producing hepatocellular carcinoma receptor A3 (EphA3) and androgen receptor (AR) protein expression levels and prognosis in prostate cancer (PCa) to better understand the role of EphA3 in the prognosis and progression of PCa. MATERIALS: We investigated the expression of EphA3 and AR in human PCa by immunohistochemistry. RESULTS: EphA3 and AR were both significantly upregulated in PCa, with expression mainly localized to the nucleus. A high level of AR expression was found in 48.4% of 64 tumor samples, which was significantly more than in the adjacent tissue samples (15.6%) (P < 0.01). The percentage of samples expressing a high level of EphA3 was significantly greater in the PCa samples (54.7%) than in the adjacent tissue samples (20.3%) for the 64 tumors (P < 0.01). The high levels of EphA3 and AR expression in the PCa tissue samples were both correlated with the pathological stage, bladder and rectal invasion, distant metastasis, and preoperative PSA level (both P < 0.05). The survival time was significantly shorter in high levels of AR expression of patients. (P < 0.01). A high level of EphA3 in PCa patients suggests a poor prognosis (P < 0.05). Biochemical recurrence, distant metastasis, and the final scores of EphA3 and AR expression were significantly correlated with the prognosis of PCa (P < 0.05). CONCLUSIONS: Increased EphA3 expression is an independent prognostic factor for a poor outcome and decreased survival in PCa. John Wiley and Sons Inc. 2019-04-08 /pmc/articles/PMC6595293/ /pubmed/30958616 http://dx.doi.org/10.1002/jcla.22871 Text en © 2019 The Authors. Journal of Clinical Laboratory Analysis Published by Wiley Periodicals, Inc. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Articles
Duan, Xiuzhi
Xu, Xiaoming
Yin, Binbin
Hong, Bong
Liu, Weiwei
Liu, Qian
Tao, Zhihua
The prognosis value of EphA3 and the androgen receptor in prostate cancer treated with radical prostatectomy
title The prognosis value of EphA3 and the androgen receptor in prostate cancer treated with radical prostatectomy
title_full The prognosis value of EphA3 and the androgen receptor in prostate cancer treated with radical prostatectomy
title_fullStr The prognosis value of EphA3 and the androgen receptor in prostate cancer treated with radical prostatectomy
title_full_unstemmed The prognosis value of EphA3 and the androgen receptor in prostate cancer treated with radical prostatectomy
title_short The prognosis value of EphA3 and the androgen receptor in prostate cancer treated with radical prostatectomy
title_sort prognosis value of epha3 and the androgen receptor in prostate cancer treated with radical prostatectomy
topic Research Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6595293/
https://www.ncbi.nlm.nih.gov/pubmed/30958616
http://dx.doi.org/10.1002/jcla.22871
work_keys_str_mv AT duanxiuzhi theprognosisvalueofepha3andtheandrogenreceptorinprostatecancertreatedwithradicalprostatectomy
AT xuxiaoming theprognosisvalueofepha3andtheandrogenreceptorinprostatecancertreatedwithradicalprostatectomy
AT yinbinbin theprognosisvalueofepha3andtheandrogenreceptorinprostatecancertreatedwithradicalprostatectomy
AT hongbong theprognosisvalueofepha3andtheandrogenreceptorinprostatecancertreatedwithradicalprostatectomy
AT liuweiwei theprognosisvalueofepha3andtheandrogenreceptorinprostatecancertreatedwithradicalprostatectomy
AT liuqian theprognosisvalueofepha3andtheandrogenreceptorinprostatecancertreatedwithradicalprostatectomy
AT taozhihua theprognosisvalueofepha3andtheandrogenreceptorinprostatecancertreatedwithradicalprostatectomy
AT duanxiuzhi prognosisvalueofepha3andtheandrogenreceptorinprostatecancertreatedwithradicalprostatectomy
AT xuxiaoming prognosisvalueofepha3andtheandrogenreceptorinprostatecancertreatedwithradicalprostatectomy
AT yinbinbin prognosisvalueofepha3andtheandrogenreceptorinprostatecancertreatedwithradicalprostatectomy
AT hongbong prognosisvalueofepha3andtheandrogenreceptorinprostatecancertreatedwithradicalprostatectomy
AT liuweiwei prognosisvalueofepha3andtheandrogenreceptorinprostatecancertreatedwithradicalprostatectomy
AT liuqian prognosisvalueofepha3andtheandrogenreceptorinprostatecancertreatedwithradicalprostatectomy
AT taozhihua prognosisvalueofepha3andtheandrogenreceptorinprostatecancertreatedwithradicalprostatectomy